GSK breathes easy
May 3, 2016
AUSTRALIA'S largest supplier
of vaccines to the Government’s
National Immunisation Programme,
GlaxoSmithKline Australia (GSK),
has reported its 2015 results to
the Australian Securities and
Investment Commission (ASIC) with
strong input from its respiratory
business.
The company reported revenue of
$925m for its continuing operations
and a profit before tax of $17.6m
in 2015.
The report included Consumer
Healthcare, a joint venture with
Novartis since March last year, and
ViiV, a joint venture with Pfizer and
Shionogi focused on HIV.
GSK holds a controlling equity
interest globally of 63.5% since it
acquired Novartis’ global vaccine
business, excluding influenza
vaccines, and GSK divested its
marketed oncology portfolio.
Also in 2015, GSK completed the
sale of its Australian-based Opiates
business to Sun Pharmaceuticals.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 May 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 May 16